Unicycive Therapeutics Q3 net loss widens to $6 mln

Unicycive Therapeutics

12/11/2025 12:13

Overview

Unicycive reports Q3 net loss of $6.0 mln, up from $4.1 mln year-over-year

Company plans to resubmit NDA for OLC by year-end after FDA discussions

Unicycive ends Q3 with $42.7 mln cash, runway into 2027

Outlook

Unicycive plans to resubmit NDA for OLC by year-end

Company expects cash runway into 2027

Unicycive anticipates potential OLC launch next year

Result Drivers

NDA RESUBMISSION - Co plans to resubmit NDA for OLC by year-end after positive FDA discussions and vendor inspection

PILL BURDEN REDUCTION - OLC significantly reduced pill burden compared to current phosphate binders, as presented at ASN

CASH POSITION - Ended Q3 with $42.7 mln cash, providing runway into 2027

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$6.01 mln
Q3 Income from Operations
-$7.34 mln
Q3 Operating Expenses
$7.34 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Unicycive Therapeutics Inc is $45.00, about 89.4% above its November 11 closing price of $4.79

Press Release: ID:nGNX4M6pLf

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)